Eli Lilly PT receives Investment Bank Analyst Rating Update
- ByInvesting.com-
By Yasin Ebrahim Investing.com -- The Dow closed flat Thursday, as investors piled in on tech stocks following a rally in Meta, though weakness in health care and energy weighed on...
By Liz Moyer Investing.com -- Stocks were rising on a Meta-fueled tech rally that lifted the Nasdaq more than 3% on Thursday. Here are the midday movers for Feb.2. Meta Platforms...
Eli Lilly came out with quarterly earnings of $2.09 per share.
The U.S. stock market is on track for its worst year since 2008, with the S&P 500 down 19.6% year-to-date. The market’s trajectory in 2023 will continue to be dictated by...
Rising rates, accelerating inflation, and slowing economy hammered S&P 500 Energy and healthcare shares have been the market’s top gainers Investors should consider...
Eli Lilly and Company is engaged in a drug manufacturing business. The Company discovers, develops, manufactures, and markets products in the human pharmaceutical products segment. Its diabetes products include Basaglar, Humalog, Humulin, Jardiance, Trajenta, and Trulicity. Its oncology products consist of Alimta, Cyramza, Erbitux, Retevmo, Tyvyt, and Verzenio. Its immunology products include Olumiant, Baricitinib, and Taltz. Its neuroscience products include Cymbalta, Emgality, and Zyprexa. Its other therapies consist of Bamlanivimab and etesevimab, Bebtelovimab, Cialis, and Forteo. It maintains special business groups to service wholesalers, pharmacy benefit managers, managed care organizations, group purchasing organizations, government and long-term care institutions, hospitals, and certain retail pharmacies. It manufactures and distributes its products through facilities in the United States, including Puerto Rico, and other countries. Its products are sold in about 120 countries.
| Average | 388.40 (+13.99% Upside) |
| High | 455.00 |
| Low | 268.00 |
| Price | 340.73 |
| No. of Analysts | 22 |
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Sell | Neutral | Neutral | Sell | Buy |
| Technical Indicators | Strong Sell | Strong Sell | Strong Buy | Sell | Strong Buy |
| Summary | Strong Sell | Sell | Buy | Sell | Strong Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 265.00 | 270.00 | 270.00 | +5.00 | +1.89% | 166.35K | Lagos | |||
| 63.90 | 63.90 | 63.90 | +0.90 | +1.43% | 27.80K | Lagos | |||
| 0.50 | 0.50 | 0.50 | 0.00 | 0.00% | 0.00 | Lagos | |||
| 0.98 | 0.98 | 0.98 | 0.00 | 0.00% | 700.00 | Lagos | |||
| 25.15 | 25.15 | 25.00 | -0.10 | -0.40% | 17.03M | Lagos | |||
| 1,081.10 | 1,081.10 | 1,081.10 | +0.80 | +0.07% | 9.59K | Lagos | |||
| 2.20 | 2.21 | 2.19 | -0.020 | -0.90% | 1.14M | Lagos | |||
| 40.00 | 40.00 | 40.00 | -1.80 | -4.31% | 407.57K | Lagos | |||
| 11.90 | 11.90 | 11.80 | -0.10 | -0.84% | 6.59M | Lagos | |||
| 22.25 | 22.30 | 22.25 | 0.00 | 0.00% | 0.00 | Lagos | |||
| 28.90 | 28.90 | 28.90 | -1.05 | -3.51% | 453.86K | Lagos | |||
| 15.60 | 15.60 | 15.60 | -1.30 | -7.69% | 306.54K | Lagos | |||
| 5.89 | 5.90 | 5.67 | +0.100 | +1.72% | 1.82M | Lagos | |||
| 8.35 | 8.40 | 8.35 | -0.05 | -0.60% | 7.74M | Lagos | |||
| 4.60 | 4.60 | 4.60 | 0.00 | 0.00% | 439.36K | Lagos |